ACADIA PHARMACEUTICALS INC
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
ACAD$16.50-22.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| March 31,2026 | December 31,2025 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Cash and cash equivalents | $282,212 | $177,695 |
| Investment securities, available-for-sale | 569,246 | 641,991 |
| Accounts receivable, net | 135,350 | 121,457 |
| Interest and other receivables | 13,034 | 26,774 |
| Inventory | 31,574 | 34,670 |
| Prepaid expenses | 64,600 | 59,526 |
| Total current assets | 1,096,016 | 1,062,113 |
| Property and equipment, net | 14,652 | 7,511 |
| Operating lease right-of-use assets | 46,274 | 47,354 |
| Intangible assets, net | 106,171 | 108,893 |
| Restricted cash | 7,846 | 7,845 |
| Long-term inventory | 80,719 | 76,704 |
| Deferred tax assets | 249,624 | 249,879 |
| Other assets | 3,928 | 3,896 |
| Total assets | $1,605,230 | $1,564,195 |
| Liabilities and stockholders’ equity | ||
| Accounts payable | $12,246 | $10,903 |
| Accrued liabilities | 293,278 | 266,211 |
| Total current liabilities | 305,524 | 277,114 |
| Operating lease liabilities | 39,003 | 40,554 |
| Other long-term liabilities | 12,637 | 19,137 |
| Total liabilities | 357,164 | 336,805 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 225,000,000 shares authorized at March 31, 2026 and December 31, 2025; 171,086,205 shares and 170,309,376 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 16 | 16 |
| Additional paid-in capital | 3,058,362 | 3,039,315 |
| Accumulated deficit | (1,809,749) | (1,813,386) |
| Accumulated other comprehensive (loss) income | (563) | 1,445 |
| Total stockholders’ equity | 1,248,066 | 1,227,390 |
| Total liabilities and stockholders’ equity | $1,605,230 | $1,564,195 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.